Compare Amphastar Pharmaceuticals Inc (AMPH) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs ProShares UltraPro S&P500 — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while ProShares UltraPro S&P500 trades at $153.59. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | UPRO | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $30.81 | $155.10 |
52-Week Low | $16.87 | $89.29 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
UPRO trades at $155.10, up 1.72% on the day, with a bullish technical signal from moving averages and a neutral oscillator reading. The stock faces resistance near $156 and support at $154, while the RSI indicates potential overbought conditions. Recent news highlights S&P 500 strength, with JPMorgan raising its 2026 target to 8,000, driven by AI-driven earnings growth and robust corporate performance.
The outlook remains positive amid strong market momentum, but risks include overvaluation concerns and sensitivity to economic data. Upside potential hinges on sustained earnings growth, while pullbacks may occur if breadth weakens or inflation fears resurface.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
